Glaukos Corporation (GKOS)

Environment story

Glaukos discloses minimal environmental data. No Scope 1, Scope 2, or Scope 3 emissions figures are reported in the 10-K. No renewable energy percentage is disclosed. No net-zero target year is identified. The company operates manufacturing and R&D facilities in California, Massachusetts, and Alabama (under construction), but provides no carbon footprint or decarbonization commitments. No environmental controversies, litigation, or fines related to toxic waste, water consumption, or habitat damage are disclosed. The lack of disclosed emissions and targets results in a baseline deduction of 15 points for undisclosed Scope 3, and another 15 points for absent net-zero target or disclosure (after 2045 equivalent). Absence of verifiable physical decarbonization infrastructure prevents any offsetting credits.

Social story

Glaukos provides limited social disclosure in the 10-K. No CEO-to-median-worker pay ratio is explicitly stated; insufficient data to assess whether it exceeds 200:1 threshold. No union-suppression activities, NLRB complaints, strikes, or major labor litigation within 24 months are disclosed. Workforce diversity (women %, underrepresented racial/ethnic groups %) is not disclosed in the filing. Leadership diversity metrics for executive and board positions are not provided in the 10-K. No supply-chain labor audits, human-rights assessments, or cobalt/lithium sourcing disclosures are mentioned. The company operates globally with manufacturing partners and distribution in multiple countries but does not disclose supply-chain ethical due diligence. Absence of documented union-suppression does not yield points; absence of positive union agreements also noted. The combination of undisclosed diversity and unverified supply-chain practices results in a conservative penalty for diversity under 30% (estimated; unconfirmed), reducing the score by 15 points.

Governance story

Glaukos does not disclose a dual-class share structure in the 10-K; common stock listed on NYSE with single class indicated. Board independence percentage is not explicitly stated in the 10-K filing. No lobbying expenditure figures are disclosed in the document. No active antitrust, consumer-safety, or fraud regulatory proceedings are mentioned. The company is a large accelerated filer and confirms compliance with Sarbanes-Oxley Section 404(b) attestation. No consent decrees, SEC fines, or significant regulatory penalties are disclosed. The lack of explicit board independence data prevents precise scoring but no red flags for supermajority founder control are evident. Absence of disclosed lobbying spending against environmental or consumer-protection deregulation suggests neutral stance, though lack of transparency prevents full credit.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Glaukos Corporation. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Glaukos Corporation in the app for interactive charts and portfolio building.

More in Healthcare